SG11202105573PA - Methods of treating myelodysplastic syndrome - Google Patents
Methods of treating myelodysplastic syndromeInfo
- Publication number
- SG11202105573PA SG11202105573PA SG11202105573PA SG11202105573PA SG11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA SG 11202105573P A SG11202105573P A SG 11202105573PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- myelodysplastic syndrome
- treating myelodysplastic
- treating
- syndrome
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862772861P | 2018-11-29 | 2018-11-29 | |
US201962811271P | 2019-02-27 | 2019-02-27 | |
US201962860557P | 2019-06-12 | 2019-06-12 | |
PCT/US2019/063372 WO2020112854A1 (en) | 2018-11-29 | 2019-11-26 | Methods of treating myelodysplastic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105573PA true SG11202105573PA (en) | 2021-06-29 |
Family
ID=70849825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105573PA SG11202105573PA (en) | 2018-11-29 | 2019-11-26 | Methods of treating myelodysplastic syndrome |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200171072A1 (en) |
EP (1) | EP3887537A4 (en) |
JP (2) | JP2022513162A (en) |
KR (1) | KR20210110303A (en) |
CN (1) | CN113631719A (en) |
AU (1) | AU2019389005A1 (en) |
BR (1) | BR112021010406A2 (en) |
CA (1) | CA3120704A1 (en) |
CL (1) | CL2021001386A1 (en) |
IL (1) | IL283054A (en) |
MX (1) | MX2021006131A (en) |
SG (1) | SG11202105573PA (en) |
TW (1) | TW202038973A (en) |
WO (1) | WO2020112854A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116189765B (en) * | 2023-02-23 | 2023-08-15 | 上海捷易生物科技有限公司 | iPS cytogenetic risk assessment system and application |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8460872B2 (en) * | 2011-04-29 | 2013-06-11 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
US20150005250A1 (en) * | 2011-10-13 | 2015-01-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome |
US9375485B2 (en) * | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
WO2019023667A1 (en) * | 2017-07-28 | 2019-01-31 | Janssen Biotech, Inc. | Methods of treating myelodysplastic syndrome |
-
2019
- 2019-11-26 WO PCT/US2019/063372 patent/WO2020112854A1/en active Application Filing
- 2019-11-26 EP EP19891290.9A patent/EP3887537A4/en active Pending
- 2019-11-26 BR BR112021010406-2A patent/BR112021010406A2/en unknown
- 2019-11-26 CN CN201980090510.3A patent/CN113631719A/en active Pending
- 2019-11-26 CA CA3120704A patent/CA3120704A1/en active Pending
- 2019-11-26 KR KR1020217019405A patent/KR20210110303A/en not_active Application Discontinuation
- 2019-11-26 US US16/696,103 patent/US20200171072A1/en active Pending
- 2019-11-26 MX MX2021006131A patent/MX2021006131A/en unknown
- 2019-11-26 JP JP2021531007A patent/JP2022513162A/en active Pending
- 2019-11-26 SG SG11202105573PA patent/SG11202105573PA/en unknown
- 2019-11-26 AU AU2019389005A patent/AU2019389005A1/en active Pending
- 2019-11-28 TW TW108143346A patent/TW202038973A/en unknown
-
2021
- 2021-05-10 IL IL283054A patent/IL283054A/en unknown
- 2021-05-27 CL CL2021001386A patent/CL2021001386A1/en unknown
-
2022
- 2022-12-07 JP JP2022195398A patent/JP2023016965A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021006131A (en) | 2021-06-23 |
AU2019389005A1 (en) | 2021-06-24 |
JP2023016965A (en) | 2023-02-02 |
TW202038973A (en) | 2020-11-01 |
IL283054A (en) | 2021-06-30 |
BR112021010406A2 (en) | 2021-08-24 |
US20200171072A1 (en) | 2020-06-04 |
WO2020112854A1 (en) | 2020-06-04 |
CA3120704A1 (en) | 2020-06-04 |
EP3887537A4 (en) | 2023-04-12 |
EP3887537A1 (en) | 2021-10-06 |
KR20210110303A (en) | 2021-09-07 |
CL2021001386A1 (en) | 2021-12-10 |
JP2022513162A (en) | 2022-02-07 |
CN113631719A (en) | 2021-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181661T1 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
ZA202006746B (en) | Methods of treatment | |
IL269371A (en) | Treatment methods | |
GB201804514D0 (en) | Treatment of pyroptosis | |
EP3634369C0 (en) | Methods for treating chemically relaxed hair | |
ZA201808607B (en) | Methods of treating prader-willi syndrome | |
IL265342A (en) | Use of pridopidine for treating rett syndrome | |
GB201813876D0 (en) | Treatment | |
IL272092A (en) | Methods of treating behavior alterations | |
PL3625375T3 (en) | Surface treatment of turbomachinery | |
EP3894768C0 (en) | Methods of cryo-curing | |
IL281792A (en) | Treatment methods | |
GB201804515D0 (en) | Treatment of necroptosis | |
GB201800546D0 (en) | Treatment | |
IL272163A (en) | Methods of treating myelodysplastic syndrome | |
IL281839A (en) | Treatment methods | |
IL283054A (en) | Methods of treating myelodysplastic syndrome | |
SG11202105877YA (en) | Method of treatment | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
GB2580157B (en) | Treatment of produced hydrocarbons | |
GB2580145B (en) | Treatment of produced hydrocarbons | |
GB201801249D0 (en) | Methods of treatment | |
IL281595A (en) | Treatment of cholangiocarcinoma | |
ZA201906319B (en) | Methods of treating depression | |
GB201814905D0 (en) | Treatment |